GlassScriptPhysician profile
Nora Saul
NPI 1801132014
$9,094.44
in general payments reported to CMS, 2019-2025
58 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,766 · 2022: $2,286 · 2023: $2,713 · 2024: $591 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,029 · Education: $12.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,029.33 |
| Education | $12.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,207.54 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $623.77 | 2021-2024 | |
| Genzyme Corporation | $472.21 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $402.50 | 2021-2025 | |
| Sk Life Science, INC. | $400.21 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $382.63 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $374.37 | 2021-2025 | Tysabri, Vumerity |
| Allergan, INC. | $294.76 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $284.93 | 2021-2023 | Ultomiris |
| Argenx US, INC. | $274.28 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $263.46 | 2021-2023 | |
| Lilly USA, LLC | $223.41 | 2021-2023 | Amyvid, Emgality, Jardiance |
| Lundbeck LLC | $216.89 | 2021-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $205.12 | 2022-2025 | Infinity |
| Amneal Pharmaceuticals LLC | $190.38 | 2021-2025 | Rytary, Ongentys |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $179.56 | 2021-2025 | Valtoco |
| Csl Behring | $171.80 | 2021-2025 | Hizentra, Privigen |
| Boston Scientific Corporation | $158.82 | 2021-2023 | |
| Harmony Biosciences LLC | $155.70 | 2021-2023 | Wakix |
| Impel Pharmaceuticals INC. | $142.44 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $137.65 | 2022-2023 | Uplizna |
| Upsher-Smith Laboratories LLC | $131.78 | 2021-2023 | |
| Amgen INC. | $129.40 | 2021-2023 | Enbrel |
| Inspire Medical Systems, INC. | $128.25 | 2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $122.38 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $119.26 | 2021-2023 | Hetlioz |
| Pfizer INC. | $115.78 | 2021-2023 | |
| Corium, LLC | $112.56 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $110.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $104.26 | 2021-2023 | Ponvory |
| Medtronic, INC. | $104.00 | 2024 | Linq II |
| Neurocrine Biosciences, INC. | $90.70 | 2021-2023 | Ongentys |
| Janssen Biotech, INC. | $89.37 | 2024 | Tremfya, Simponi Aria |
| Celgene Corporation | $88.98 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.04 | 2022 | |
| Kyowa Kirin, INC. | $82.12 | 2021-2022 | |
| Emd Serono, INC. | $72.87 | 2022-2023 | Mavenclad |
| Aucta Pharmaceuticals, INC. | $61.83 | 2025 | Motpoly Xr |
| Banner Life Sciences, LLC | $57.30 | 2022-2023 | |
| Eisai INC. | $56.88 | 2023 | |
| Acorda Therapeutics, INC | $51.72 | 2022 | |
| Ge Healthcare | $43.47 | 2023-2024 | |
| Grifols USA, LLC | $43.05 | 2022-2023 | Gamunex-C |
| Tanabe Pharma America, INC. | $38.11 | 2021-2023 | |
| Amylyx Pharmaceuticals, INC. | $33.40 | 2023 | Relyvrio |
| Livanova USA, INC. | $32.63 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $23.51 | 2021 | Xyosted, Tlando |
| Cala Health, INC. | $22.08 | 2023 | Cala Kiq, Cala Trio |
| Genentech USA, INC. | $21.71 | 2022 | |
| Otto Bock Healthcare LP | $21.02 | 2022 | |
| Sumitomo Pharma America, INC. | $19.48 | 2023 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $18.82 | 2023 | Fycompa |
| Scilex Pharmaceuticals INC. | $18.37 | 2023 | Ztlido |
| Avion Pharmaceuticals | $18.34 | 2023 | Dhivy |
| Arbor Pharmaceuticals, INC. | $18.25 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.88 | 2025 | Dysport |
| Halozyme INC | $16.47 | 2023 | |
| Collegium Pharmaceutical, INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Saul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.